Application of High-Efficiency Cell Expansion and High-Throughput Drug Sensitivity Screening for Leukemia Treatment

Table 1

Patient characteristics.

Disease subtype	Characteristics		(range)	HEHDS	Non-HEHDS guided	values
AML	Patients		121	79	42
	Male/female		57/64	35/44	22/20	0.397
	Median age		48	46	50	0.238
	Median marrow blast %		11.23%	11.00%	11.24%	0.325
	Genetic anomaly at initial diagnosis	Normal karyotype without any molecular abnormality	98	62	36	0.334
		FLT3-ITD	23	17	6
	Disease status	New diagnosed	43	26	17	0.408
		Relapsed	78	53	25
ALL	Patients		27	17	10
	Male/female		13/14	7/10	6/4	0.345
	Median age		37	35	39	0.195
	Median marrow blast %		10.25%	9.57%	11.15%	0.251
	Genetic anomaly at initial diagnosis	Normal karyotype without any molecular abnormality	18	11	7	0.778
		BCR-ABL	9	6	3
	Disease status	New diagnosed	11	7	4	0.952
		Relapsed	16	10	6